Key insights
- Oracle appointed Cleveland Clinic CEO to its board, signaling its continued expansion in healthcare technology. Oppenheimer raised its price target on Oracle to $235, citing strong tech infrastructure spending. These developments suggest positive momentum for Oracle, potentially influencing market sentiment.
AUSTIN, Texas - Oracle Corporation (NYSE:ORCL) appointed Dr. Tomislav Mihaljevic to its board of directors, effective May 6, expanding the board to 13 members, according to a press release statement issued today.
Dr. Mihaljevic serves as Chief Executive Officer and President of Cleveland Clinic, a nonprofit multispecialty academic medical center, a position he has held since January 2018. He previously led Cleveland Clinic Abu Dhabi from 2015 to 2017 and joined Cleveland Clinic in 2004 as a surgeon in the Department of Thoracic and Cardiovascular Surgery. He previously served as a director of GE HealthCare.
"Tom is one of the world’s leading healthcare executives, with deep experience managing complex clinical organizations, advancing patient care, and expanding access to high-quality healthcare around the world," said Mike Sicilia, Oracle Chief Executive Officer.The appointment comes as Oracle, with a market capitalization of $536 billion and revenue of $64 billion, continues expanding its healthcare technology footprint. The company posted revenue growth of nearly 15% in the last twelve months.
Clay Magouyrk, Oracle’s Chief Executive Officer, stated that Dr. Mihaljevic’s perspective would be valuable as Oracle works with healthcare organizations on technology solutions.
Bruce Chizen, Chair of Oracle’s Nomination and Governance Committee, said Dr. Mihaljevic’s leadership at Cleveland Clinic provides understanding of challenges facing healthcare systems globally.
Board members serve one-year terms and will stand for election at the company’s annual stockholders meeting in November 2026.
In other recent news, Oracle has been the focus of several key developments. Oppenheimer has raised its price target for Oracle to $235, up from $210, while maintaining an Outperform rating. This adjustment reflects strong technology infrastructure spending and a significant restructuring that affected 18% of Oracle’s workforce. Meanwhile, Oracle is also playing a crucial role in supporting the Africa Clinical Research Network’s first clinical trial, using its technology platform to aid in a study across Zimbabwe, Rwanda, and Tanzania.
In another development, Oracle has expressed excitement about its partnership with OpenAI, despite investor concerns following reports that OpenAI missed key user and revenue targets. This partnership remains a focal point for Oracle as it aims to expand its capacity for artificial intelligence applications. Additionally, Goldman Sachs has recommended focusing on hyperscalers, like Oracle, over chipmakers for AI infrastructure investments, highlighting Oracle’s strategic positioning in this sector. These recent developments underscore Oracle’s ongoing initiatives and market positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.